GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Total Liabilities

SWOBY (Swedish Orphan Biovitrum AB) Total Liabilities : $3,430 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Total Liabilities?

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Sep. 2024 was $3,430 Mil.

Swedish Orphan Biovitrum AB's quarterly Total Liabilities declined from Mar. 2024 ($3,709.05 Mil) to Jun. 2024 ($3,510.73 Mil) and declined from Jun. 2024 ($3,510.73 Mil) to Sep. 2024 ($3,430.05 Mil).

Swedish Orphan Biovitrum AB's annual Total Liabilities declined from Dec. 2021 ($2,800.78 Mil) to Dec. 2022 ($2,502.51 Mil) but then increased from Dec. 2022 ($2,502.51 Mil) to Dec. 2023 ($3,915.15 Mil).


Swedish Orphan Biovitrum AB Total Liabilities Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Total Liabilities Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,045.67 3,357.25 2,800.78 2,502.51 3,915.15

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,711.21 3,915.15 3,709.05 3,510.73 3,430.05

Swedish Orphan Biovitrum AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Swedish Orphan Biovitrum AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1861.547+(1123.46+909.666
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+20.473)
=3,915

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=7216.795-3301.65
=3,915

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1358.979+(1146.446+924.627
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3,430

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=7057.875-3627.823
=3,430

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).